Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

N Acquavella, H Kluger, J Rhee, L Farber… - Journal of …, 2008 - journals.lww.com
The standard q8h high-dose interleukin-2 (IL-2) regimen produces clear benefit for a subset
of patients, but has limited acceptance because of its substantial acute toxicity including
hypotension requiring pressors in 30% to 50%, the schedule is inconvenient for medical staff
who must assess patients before each dose, and in some hospitals, the limited availability of
monitored beds. We initiated a high-dose IL-2 program with a modified twice daily dosing
schedule, limited the total number of doses per course to 8, and treated patients in an …